Weifan Jiang

616 total citations
34 papers, 441 citations indexed

About

Weifan Jiang is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Weifan Jiang has authored 34 papers receiving a total of 441 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 7 papers in Organic Chemistry and 6 papers in Oncology. Recurrent topics in Weifan Jiang's work include Cancer therapeutics and mechanisms (6 papers), Histone Deacetylase Inhibitors Research (5 papers) and Quinazolinone synthesis and applications (5 papers). Weifan Jiang is often cited by papers focused on Cancer therapeutics and mechanisms (6 papers), Histone Deacetylase Inhibitors Research (5 papers) and Quinazolinone synthesis and applications (5 papers). Weifan Jiang collaborates with scholars based in China, Australia and Montenegro. Weifan Jiang's co-authors include Zhen Wang, Lizhen Huang, Renke Dai, Yang Zhou, Junshan Liu, Qingmei Xie, Jinyi Yang, Honghua Zhang, Linsheng Zhuo and Ying Peng and has published in prestigious journals such as Journal of Medicinal Chemistry, Frontiers in Microbiology and Experimental Cell Research.

In The Last Decade

Weifan Jiang

32 papers receiving 436 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Weifan Jiang China 11 258 69 60 44 43 34 441
Shufang Hu China 11 138 0.5× 75 1.1× 36 0.6× 17 0.4× 30 0.7× 22 337
Mohanapriya Arumugam India 13 158 0.6× 77 1.1× 23 0.4× 23 0.5× 22 0.5× 39 421
Federica Sarno Italy 14 277 1.1× 56 0.8× 62 1.0× 14 0.3× 35 0.8× 27 490
Yunyun Zhu China 16 165 0.6× 77 1.1× 25 0.4× 21 0.5× 44 1.0× 38 517
Kun-Tzu Li Taiwan 6 223 0.9× 29 0.4× 34 0.6× 23 0.5× 36 0.8× 8 411
Ekram Saleh Egypt 16 395 1.5× 86 1.2× 153 2.5× 15 0.3× 41 1.0× 24 653
Ruirui Yang China 13 243 0.9× 35 0.5× 44 0.7× 11 0.3× 24 0.6× 36 493
Hong‐Lin Chan Taiwan 12 186 0.7× 17 0.2× 47 0.8× 18 0.4× 41 1.0× 22 405
Hongyan Guo China 12 171 0.7× 90 1.3× 24 0.4× 23 0.5× 57 1.3× 28 510

Countries citing papers authored by Weifan Jiang

Since Specialization
Citations

This map shows the geographic impact of Weifan Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weifan Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weifan Jiang more than expected).

Fields of papers citing papers by Weifan Jiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weifan Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weifan Jiang. The network helps show where Weifan Jiang may publish in the future.

Co-authorship network of co-authors of Weifan Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Weifan Jiang. A scholar is included among the top collaborators of Weifan Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weifan Jiang. Weifan Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Xi, Ying Peng, Zhigang An, et al.. (2024). Structure-activity relationship study of novel evodiamine amino acid conjugates with potent anti-colorectal cancer efficacy. European Journal of Medicinal Chemistry. 283. 117132–117132. 2 indexed citations
2.
Wang, Xiaodong, Honghua Zhang, Xiao Hu, et al.. (2024). Fenamates: Forgotten treasure for cancer treatment and prevention: Mechanisms of action, structural modification, and bright future. Medicinal Research Reviews. 45(1). 164–213. 7 indexed citations
3.
Zhang, Xi, Yan Peng, Junbo Wu, et al.. (2024). Identification of a novel 10-hydroxyevodiamine prodrug as a potent topoisomerase inhibitor with improved aqueous solubility for treatment of hepatocellular carcinoma. European Journal of Medicinal Chemistry. 279. 116807–116807. 5 indexed citations
4.
Peng, Yan, Ying Peng, Weidong Zhang, et al.. (2024). Novel N-phenyl-2-(aniline) benzamide hydrochloride salt development for colon cancer therapy. Frontiers in Pharmacology. 15. 1452904–1452904. 1 indexed citations
5.
Wang, Chengkun, Weifan Jiang, Peng Xue, et al.. (2024). Discovery of novel small molecules targeting the USP21/JAK2/STAT3 axis for the treatment of triple-negative breast cancer. European Journal of Medicinal Chemistry. 273. 116500–116500. 6 indexed citations
6.
Jin, Huidong, et al.. (2023). Downscaling long lead time daily rainfall ensemble forecasts through deep learning. Stochastic Environmental Research and Risk Assessment. 37(8). 3185–3203. 6 indexed citations
7.
Zhuo, Linsheng, Siyi Zhang, Mingshu Wang, et al.. (2023). Structure-activity relationship study of 1,6-naphthyridinone derivatives as selective type II AXL inhibitors with potent antitumor efficacy. European Journal of Medicinal Chemistry. 265. 116090–116090. 3 indexed citations
8.
Li, Shuang, Yanli He, Yan Peng, et al.. (2023). Development of o-aminobenzamide salt derivatives for improving water solubility and anti-undifferentiated gastric cancer. Frontiers in Pharmacology. 14. 1118397–1118397. 3 indexed citations
9.
Wang, Shuzhi, Shan Duan, Linsheng Zhuo, et al.. (2023). Exploring the Therapeutic Effects of Multifunctional N-Salicylic Acid Tryptamine Derivative against Parkinson’s Disease. ACS Omega. 8(31). 28910–28923. 5 indexed citations
10.
Deng, Xuemei, Tian Luo, Xi Zhang, et al.. (2022). Design, synthesis and biological evaluation of 3-arylisoquinoline derivatives as topoisomerase I and II dual inhibitors for the therapy of liver cancer. European Journal of Medicinal Chemistry. 237. 114376–114376. 10 indexed citations
11.
Wang, Zhen, Ying Peng, Xi Zhang, et al.. (2022). Natural product evodiamine-inspired medicinal chemistry: Anticancer activity, structural optimization and structure-activity relationship. European Journal of Medicinal Chemistry. 247. 115031–115031. 36 indexed citations
12.
Hu, Xiao, Junfang Li, Honghua Zhang, et al.. (2022). Discovery of dual inhibitors of topoisomerase I and Cyclooxygenase-2 for colon cancer therapy. European Journal of Medicinal Chemistry. 240. 114560–114560. 9 indexed citations
13.
Lu, Ying‐Mei, Li Zhao, Junfang Li, et al.. (2021). Novel piperazine based benzamide derivatives as potential anti-glioblastoma agents inhibiting cell proliferation and cell cycle progression. European Journal of Medicinal Chemistry. 227. 113908–113908. 8 indexed citations
14.
Lu, Ying‐Mei, Junfang Li, Honghua Zhang, et al.. (2021). Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo. European Journal of Medicinal Chemistry. 227. 113888–113888. 17 indexed citations
15.
Jiang, Weifan, et al.. (2021). Influence of two-period cross-over design on the bioequivalence study of gefitinib tablets in beagle dogs. European Journal of Pharmaceutical Sciences. 165. 105933–105933. 1 indexed citations
16.
Jiang, Weifan, et al.. (2020). Roles of diclofenac and its metabolites in immune activation associated with acute hepatotoxicity in TgCYP3A4/hPXR-humanized mice. International Immunopharmacology. 86. 106723–106723. 10 indexed citations
17.
Zou, Yan, Cheng Cheng, Xiongbing Lu, et al.. (2020). FAT10 promotes the progression of bladder cancer by upregulating HK2 through the EGFR/AKT pathway. Experimental Cell Research. 398(1). 112401–112401. 18 indexed citations
18.
Jiang, Weifan, et al.. (2019). Studies of pharmacokinetics in beagle dogs and drug-drug interaction potential of a novel selective ZAK inhibitor 3h for hypertrophic cardiomyopathy treatment. Journal of Pharmaceutical and Biomedical Analysis. 172. 206–213. 2 indexed citations
19.
Jiang, Weifan, et al.. (2018). Comparison of in vitro/in vivo blood distribution and pharmacokinetics of artemisinin, artemether and dihydroartemisinin in rats. Journal of Pharmaceutical and Biomedical Analysis. 162. 140–148. 22 indexed citations
20.
Jiang, Weifan, et al.. (2014). Association of CYP1B1 L432V polymorphism with urinary cancer susceptibility: a meta-analysis. Diagnostic Pathology. 9(1). 113–113. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shufang Hu Breakdown of academic impact, for papers by Mohanapriya Arumugam Breakdown of academic impact, for papers by Federica Sarno Breakdown of academic impact, for papers by Yunyun Zhu Breakdown of academic impact, for papers by Kun-Tzu Li Breakdown of academic impact, for papers by Ekram Saleh Breakdown of academic impact, for papers by Ruirui Yang Breakdown of academic impact, for papers by Hong‐Lin Chan Breakdown of academic impact, for papers by Hongyan Guo
Rankless by CCL
2026